Remdesivir therapy for severe pediatric COVID‐19 in Singapore: A single‐center retrospective observational cohort study
Abstract Background and Aims There is a paucity of information on remdesivir (RDV) use in severe pediatric coronavirus disease 2019 (COVID‐19). We aimed to explore the effectiveness of RDV as the cumulative proportion of pediatric COVID‐19 patients deescalated from Day 5 of high dependency or intens...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2023-12-01
|
| Series: | Health Science Reports |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/hsr2.1698 |
| _version_ | 1797375170377154560 |
|---|---|
| author | Valerie Xue Fen Seah Rina Yue Ling Ong Kai Qian Kam Koh Cheng Thoon Natalie Woon Hui Tan Jiahui Li Karen Donceras Nadua Chia Yin Chong Chee Fu Yung |
| author_facet | Valerie Xue Fen Seah Rina Yue Ling Ong Kai Qian Kam Koh Cheng Thoon Natalie Woon Hui Tan Jiahui Li Karen Donceras Nadua Chia Yin Chong Chee Fu Yung |
| author_sort | Valerie Xue Fen Seah |
| collection | DOAJ |
| description | Abstract Background and Aims There is a paucity of information on remdesivir (RDV) use in severe pediatric coronavirus disease 2019 (COVID‐19). We aimed to explore the effectiveness of RDV as the cumulative proportion of pediatric COVID‐19 patients deescalated from Day 5 of high dependency or intensive care unit (HD/ICU). Methods All children ≤18 years admitted to Singapore's largest pediatric hospital from January 1, 2020 to March 18, 2022 were reviewed retrospectively. Patients were included if they were positive for severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) on reverse transcriptase polymerase chain reaction, required oxygen, and HD/ICU care. The characteristics and outcomes of those who received RDV or not (no‐RDV) were compared. Results We reviewed 15 children with a median age of 2.5 years (interquartile range [IQR]: 0.8–11.0), of which 7 (46.7%) received RDV. There was no difference in cumulative proportion of children deescalated from Day 5 of HD/ICU care in the RDV versus the no‐RDV group (5/7, 70% vs. 7/8, 87.5%, p = 0.57). The RDV versus no‐RDV group had higher disease severity, that is, WHO Ordinal Scale scores (median 6, IQR: 5–7 vs. 5, IQR: 4–5, p = 0.03), higher procalcitonin levels (ug/L) (median 4.31, IQR: 0.8–24.2 vs. 0.12, IQR: 0.09–0.26, p = 0.02), and longer HD/ICU care days (median 5, IQR: 4–9, vs. 1, IQR: 1–4, p = 0.01). There was no significant difference in hospitalization days. There were no adverse events directly attributable to RDV. None died from COVID‐19 infection. Conclusion Our observational analysis was unable to detect any clear benefit of RDV in terms of reducing duration in HD/ICU. RDV was well‐tolerated in children with severe COVID‐19. |
| first_indexed | 2024-03-08T19:18:23Z |
| format | Article |
| id | doaj.art-4db82011dea746e9b93cf073fb3c4219 |
| institution | Directory Open Access Journal |
| issn | 2398-8835 |
| language | English |
| last_indexed | 2024-03-08T19:18:23Z |
| publishDate | 2023-12-01 |
| publisher | Wiley |
| record_format | Article |
| series | Health Science Reports |
| spelling | doaj.art-4db82011dea746e9b93cf073fb3c42192023-12-27T00:48:32ZengWileyHealth Science Reports2398-88352023-12-01612n/an/a10.1002/hsr2.1698Remdesivir therapy for severe pediatric COVID‐19 in Singapore: A single‐center retrospective observational cohort studyValerie Xue Fen Seah0Rina Yue Ling Ong1Kai Qian Kam2Koh Cheng Thoon3Natalie Woon Hui Tan4Jiahui Li5Karen Donceras Nadua6Chia Yin Chong7Chee Fu Yung8Department of Pharmacy KK Women's and Children's Hospital Singapore SingaporeDepartment of Pharmacy KK Women's and Children's Hospital Singapore SingaporeInfectious Disease Service, Department of Paediatrics KK Women's and Children's Hospital Singapore SingaporeInfectious Disease Service, Department of Paediatrics KK Women's and Children's Hospital Singapore SingaporeInfectious Disease Service, Department of Paediatrics KK Women's and Children's Hospital Singapore SingaporeInfectious Disease Service, Department of Paediatrics KK Women's and Children's Hospital Singapore SingaporeInfectious Disease Service, Department of Paediatrics KK Women's and Children's Hospital Singapore SingaporeInfectious Disease Service, Department of Paediatrics KK Women's and Children's Hospital Singapore SingaporeInfectious Disease Service, Department of Paediatrics KK Women's and Children's Hospital Singapore SingaporeAbstract Background and Aims There is a paucity of information on remdesivir (RDV) use in severe pediatric coronavirus disease 2019 (COVID‐19). We aimed to explore the effectiveness of RDV as the cumulative proportion of pediatric COVID‐19 patients deescalated from Day 5 of high dependency or intensive care unit (HD/ICU). Methods All children ≤18 years admitted to Singapore's largest pediatric hospital from January 1, 2020 to March 18, 2022 were reviewed retrospectively. Patients were included if they were positive for severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) on reverse transcriptase polymerase chain reaction, required oxygen, and HD/ICU care. The characteristics and outcomes of those who received RDV or not (no‐RDV) were compared. Results We reviewed 15 children with a median age of 2.5 years (interquartile range [IQR]: 0.8–11.0), of which 7 (46.7%) received RDV. There was no difference in cumulative proportion of children deescalated from Day 5 of HD/ICU care in the RDV versus the no‐RDV group (5/7, 70% vs. 7/8, 87.5%, p = 0.57). The RDV versus no‐RDV group had higher disease severity, that is, WHO Ordinal Scale scores (median 6, IQR: 5–7 vs. 5, IQR: 4–5, p = 0.03), higher procalcitonin levels (ug/L) (median 4.31, IQR: 0.8–24.2 vs. 0.12, IQR: 0.09–0.26, p = 0.02), and longer HD/ICU care days (median 5, IQR: 4–9, vs. 1, IQR: 1–4, p = 0.01). There was no significant difference in hospitalization days. There were no adverse events directly attributable to RDV. None died from COVID‐19 infection. Conclusion Our observational analysis was unable to detect any clear benefit of RDV in terms of reducing duration in HD/ICU. RDV was well‐tolerated in children with severe COVID‐19.https://doi.org/10.1002/hsr2.1698childrenpediatricremdesivirSARS‐CoV‐2severe COVID‐19 |
| spellingShingle | Valerie Xue Fen Seah Rina Yue Ling Ong Kai Qian Kam Koh Cheng Thoon Natalie Woon Hui Tan Jiahui Li Karen Donceras Nadua Chia Yin Chong Chee Fu Yung Remdesivir therapy for severe pediatric COVID‐19 in Singapore: A single‐center retrospective observational cohort study Health Science Reports children pediatric remdesivir SARS‐CoV‐2 severe COVID‐19 |
| title | Remdesivir therapy for severe pediatric COVID‐19 in Singapore: A single‐center retrospective observational cohort study |
| title_full | Remdesivir therapy for severe pediatric COVID‐19 in Singapore: A single‐center retrospective observational cohort study |
| title_fullStr | Remdesivir therapy for severe pediatric COVID‐19 in Singapore: A single‐center retrospective observational cohort study |
| title_full_unstemmed | Remdesivir therapy for severe pediatric COVID‐19 in Singapore: A single‐center retrospective observational cohort study |
| title_short | Remdesivir therapy for severe pediatric COVID‐19 in Singapore: A single‐center retrospective observational cohort study |
| title_sort | remdesivir therapy for severe pediatric covid 19 in singapore a single center retrospective observational cohort study |
| topic | children pediatric remdesivir SARS‐CoV‐2 severe COVID‐19 |
| url | https://doi.org/10.1002/hsr2.1698 |
| work_keys_str_mv | AT valeriexuefenseah remdesivirtherapyforseverepediatriccovid19insingaporeasinglecenterretrospectiveobservationalcohortstudy AT rinayuelingong remdesivirtherapyforseverepediatriccovid19insingaporeasinglecenterretrospectiveobservationalcohortstudy AT kaiqiankam remdesivirtherapyforseverepediatriccovid19insingaporeasinglecenterretrospectiveobservationalcohortstudy AT kohchengthoon remdesivirtherapyforseverepediatriccovid19insingaporeasinglecenterretrospectiveobservationalcohortstudy AT nataliewoonhuitan remdesivirtherapyforseverepediatriccovid19insingaporeasinglecenterretrospectiveobservationalcohortstudy AT jiahuili remdesivirtherapyforseverepediatriccovid19insingaporeasinglecenterretrospectiveobservationalcohortstudy AT karendoncerasnadua remdesivirtherapyforseverepediatriccovid19insingaporeasinglecenterretrospectiveobservationalcohortstudy AT chiayinchong remdesivirtherapyforseverepediatriccovid19insingaporeasinglecenterretrospectiveobservationalcohortstudy AT cheefuyung remdesivirtherapyforseverepediatriccovid19insingaporeasinglecenterretrospectiveobservationalcohortstudy |